# Instituto Oncológico Dr. Rosell

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/instituto-oncologico-dr-rosell/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 94 |
| Citations | 57,496 |
| City | Barcelona |
| Country | ES |
| Description | Instituto Oncológico Dr. Rosell is a research organisation in Barcelona, ES. OpenAlex records 854 works and 57,496 citations for it. 153 researchers list it as their most recent affiliation. |
| Homepage | https://www.oncorosell.com/en |
| OpenAlex ID | https://openalex.org/I4210095200 |
| Researchers | 153 |
| ROR ID | https://ror.org/00r9kn296 |
| Type | facility |
| Works | 854 |

## University papers

Showing 12 of 16.

- [Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group](https://scholariq.org/papers/lung-adjuvant-cisplatin-evaluation-a-pooled-analysis-by-the-lace-collaborative/)
- [Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/alectinib-versus-crizotinib-in-untreated-i-alk-i-positive-non-small-cell-lung/)
- [Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry](https://scholariq.org/papers/immune-checkpoint-inhibitors-for-patients-with-advanced-lung-cancer-and/)
- [Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer](https://scholariq.org/papers/activation-of-the-axl-kinase-causes-resistance-to-egfr-targeted-therapy-in-lung/)
- [Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/dacomitinib-versus-gefitinib-as-first-line-treatment-for-patients-with-egfr/)
- [Non-small-cell lung cancer](https://scholariq.org/papers/non-small-cell-lung-cancer/)
- [Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.](https://scholariq.org/papers/detection-of-aberrant-promoter-hypermethylation-of-tumor-suppressor-genes-in/)
- [Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study](https://scholariq.org/papers/updated-overall-survival-and-final-progression-free-survival-data-for-patients/)
- [Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations](https://scholariq.org/papers/improvement-in-overall-survival-in-a-randomized-study-that-compared-dacomitinib/)
- [Adjuvant chemotherapy for resected early-stage non-small cell lung cancer](https://scholariq.org/papers/adjuvant-chemotherapy-for-resected-early-stage-non-small-cell-lung-cancer/)
- [Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer](https://scholariq.org/papers/prognostic-effect-of-tumor-lymphocytic-infiltration-in-resectable-non-small-cell/)
- [Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial](https://scholariq.org/papers/activity-and-safety-of-brigatinib-in-alk-rearranged-non-small-cell-lung-cancer/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.